FDA fast-tracks Tonix Pharmaceuticals' fibromyalgia drug TNX-102 SL for sleep improvement.

The FDA has recognized fibromyalgia as a serious condition, fast-tracking Tonix Pharmaceuticals' drug candidate TNX-102 SL (cyclobenzaprine HCl sublingual tablets). The drug candidate aims to improve sleep quality without addictive properties, addressing patients' dissatisfaction with current treatments. Tonix plans to submit a new drug application to the FDA in 2024, requesting priority review for TNX-102 SL.

August 01, 2024
4 Articles